As of 2025-10-20, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.08) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.33 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -125.2%.
The range of the Relative Valuation is (0.04) - (0.13) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 2.5x - 7.7x | 5.1x |
| Forward P/E multiples | 2.4x - 7.7x | 5.0x |
| Fair Price | (0.04) - (0.13) | (0.08) |
| Upside | -112.2% - -138.3% | -125.2% |
| Date | P/E |
| 2025-10-15 | -20.16 |
| 2025-10-14 | -19.55 |
| 2025-10-10 | -20.16 |
| 2025-10-09 | -20.77 |
| 2025-10-08 | -21.38 |
| 2025-10-07 | -22.00 |
| 2025-10-06 | -20.77 |
| 2025-10-03 | -19.55 |
| 2025-10-02 | -20.16 |
| 2025-10-01 | -19.55 |
| 2025-09-30 | -20.47 |
| 2025-09-29 | -20.16 |
| 2025-09-26 | -19.55 |
| 2025-09-24 | -19.55 |
| 2025-09-23 | -20.16 |
| 2025-09-22 | -20.16 |
| 2025-09-19 | -21.38 |
| 2025-09-18 | -22.00 |
| 2025-09-16 | -22.00 |
| 2025-09-15 | -22.00 |
| 2025-09-12 | -22.61 |
| 2025-09-11 | -22.30 |
| 2025-09-09 | -22.00 |
| 2025-09-08 | -22.00 |
| 2025-09-04 | -20.77 |
| 2025-09-03 | -19.55 |
| 2025-08-29 | -22.61 |
| 2025-08-28 | -20.47 |
| 2025-08-27 | -19.55 |
| 2025-08-25 | -21.38 |
| 2025-08-22 | -22.30 |
| 2025-08-21 | -22.30 |
| 2025-08-20 | -21.38 |
| 2025-08-19 | -21.38 |
| 2025-08-18 | -22.61 |
| 2025-08-15 | -21.69 |
| 2025-08-14 | -21.69 |
| 2025-08-13 | -21.69 |
| 2025-08-12 | -22.61 |
| 2025-08-11 | -22.61 |
| 2025-08-07 | -22.00 |
| 2025-08-06 | -22.00 |
| 2025-08-05 | -22.00 |
| 2025-08-01 | -20.47 |
| 2025-07-31 | -20.47 |
| 2025-07-30 | -20.47 |
| 2025-07-29 | -20.47 |
| 2025-07-28 | -22.61 |
| 2025-07-25 | -20.16 |
| 2025-07-24 | -20.77 |